Weatherly Asset Management L. P. Invests $240,000 in Bristol-Myers Squibb Company (BMY) Stock
Weatherly Asset Management L. P. bought a new stake in Bristol-Myers Squibb Company (NYSE:BMY) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 4,309 shares of the biopharmaceutical company’s stock, valued at approximately $240,000.
A number of other large investors have also recently modified their holdings of the business. Waldron LP acquired a new position in shares of Bristol-Myers Squibb in the first quarter valued at approximately $475,000. Founders Capital Management LLC boosted its holdings in shares of Bristol-Myers Squibb by 0.7% in the first quarter. Founders Capital Management LLC now owns 4,097 shares of the biopharmaceutical company’s stock valued at $223,000 after buying an additional 29 shares during the period. Headinvest LLC boosted its holdings in shares of Bristol-Myers Squibb by 23.1% in the first quarter. Headinvest LLC now owns 12,675 shares of the biopharmaceutical company’s stock valued at $689,000 after buying an additional 2,375 shares during the period. Sit Investment Associates Inc. boosted its holdings in shares of Bristol-Myers Squibb by 3.5% in the first quarter. Sit Investment Associates Inc. now owns 9,175 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 312 shares during the period. Finally, NBT Bank N A NY boosted its holdings in shares of Bristol-Myers Squibb by 0.7% in the first quarter. NBT Bank N A NY now owns 121,122 shares of the biopharmaceutical company’s stock valued at $6,587,000 after buying an additional 879 shares during the period. 68.88% of the stock is owned by hedge funds and other institutional investors.
In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the sale, the senior vice president now owns 46,297 shares in the company, valued at approximately $2,777,820. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Theodore R. Samuels II purchased 6,000 shares of the firm’s stock in a transaction on Wednesday, August 2nd. The shares were acquired at an average price of $55.94 per share, with a total value of $335,640.00. Following the purchase, the director now directly owns 18,000 shares in the company, valued at approximately $1,006,920. The disclosure for this purchase can be found here. Insiders own 0.23% of the company’s stock.
WARNING: This piece was posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.watchlistnews.com/weatherly-asset-management-l-p-invests-240000-in-bristol-myers-squibb-company-bmy-stock/1616648.html.
Shares of Bristol-Myers Squibb Company (BMY) opened at 64.81 on Friday. The firm has a 50-day moving average of $61.56 and a 200-day moving average of $56.65. Bristol-Myers Squibb Company has a 52 week low of $46.01 and a 52 week high of $65.03. The firm has a market cap of $106.28 billion, a PE ratio of 23.67 and a beta of 1.19.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.01. The business had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. Bristol-Myers Squibb’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.69 EPS. On average, analysts expect that Bristol-Myers Squibb Company will post $2.98 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be paid a dividend of $0.39 per share. The ex-dividend date is Thursday, October 5th. This represents a $1.56 dividend on an annualized basis and a yield of 2.41%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 56.73%.
Several research analysts have recently weighed in on the stock. Credit Suisse Group set a $58.00 price target on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a report on Wednesday, August 16th. BMO Capital Markets reiterated an “underperform” rating and issued a $47.00 price target (down previously from $51.00) on shares of Bristol-Myers Squibb in a report on Wednesday, July 26th. Leerink Swann reduced their price target on shares of Bristol-Myers Squibb from $66.00 to $61.00 and set an “outperform” rating for the company in a report on Friday, July 28th. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a report on Wednesday, August 9th. Finally, Cowen and Company reiterated a “hold” rating and issued a $65.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, September 19th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and ten have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $62.38.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.